EYE Share Price Performance
AU$0.13
0.03 (30.00%)
56.7% undervalued intrinsic discount
AU$0.30
Fair Value
Price AU$0.13
AnalystLowTarget AU$0.30
AnalystConsensusTarget AU$0.37
AnalystHighTarget AU$0.50
Fair ValueAU$0.30
Share Pricen/a
Nova Eye Medical Limited Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
EYE Community Narratives
AN
Fair Value AU$0.3 56.7% undervalued intrinsic discount
US Market Dependence Will Constrain Earnings But Enable Novel Approaches
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value AU$0.37 65.2% undervalued intrinsic discount
US Demand And China Approval Will Boost Vision Care Access
0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
Fair Value AU$0.5 74.0% undervalued intrinsic discount
Aging Populations And MIGS Advances Will Expand Ophthalmic Markets
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
US Market Dependence Will Constrain Earnings But Enable Novel Approaches
Key Takeaways Heavy reliance on the US and a narrow glaucoma-focused portfolio exposes the company to policy, regulatory, and obsolescence risks. Rising competition, payer pricing pressures, and limited geographic diversification threaten profitability, margin expansion, and sustained earnings growth.Read more
46
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AU$0.3
56.7% undervalued intrinsic discount
Fair Value
Profit Margin
6.71%
Future PE
26.96x
Price in 2029
AU$0.37
Aging Populations And MIGS Advances Will Expand Ophthalmic Markets
Key Takeaways Strong adoption and product preference position Nova Eye for accelerating revenue growth, exceptional margin expansion, and higher long-term earnings beyond current expectations. Emerging drug delivery, large global patient pool, and innovation funding underpin future revenue diversification, recurring income, and a durable competitive advantage.Read more
17
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AU$0.5
74.0% undervalued intrinsic discount
Fair Value
Profit Margin
15.74%
Future PE
21x
Price in 2028
AU$0.61
US Demand And China Approval Will Boost Vision Care Access
Key Takeaways Expanding market access, clinical validation, and demographic trends are driving strong, sustained revenue and margin growth opportunities for Nova Eye Medical. Operational efficiencies, manufacturing scale, and long-term healthcare trends are enhancing profitability and supporting the company's differentiated glaucoma device portfolio.Read more
52
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
AN
AU$0.37
65.2% undervalued intrinsic discount
Fair Value
Profit Margin
15.03%
Future PE
18x
Price in 2028
AU$0.29
Trending Discussion
Recently Updated Narratives
AN
EYE: 2026 Revenue Guidance And Margin Outlook Will Support Stronger Upside Potential
Fair Value: AU$0.3 56.7% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Aging Populations And MIGS Advances Will Expand Ophthalmic Markets
Fair Value: AU$0.5 74.0% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
US Demand And China Approval Will Boost Vision Care Access
Fair Value: AU$0.37 65.2% undervalued intrinsic discount
12 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Nova Eye Medical Limited Key Details
About EYE
- Founded
- 1970
- Employees
- n/a
- CEO
- WebsiteView website
Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.
